Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

Light-chain MGUS defined as per the revised definition of the istopmm study: Experience from the university of calgary MGUS clinic

Victor Jimenez-Zepeda, Holly Lee, Etienne Mahe, Sylvia McCulloch, Jason Tay, Peter Duggan

Blood (2025) 146 (Supplement 1): 2187.

https://doi.org/10.1182/blood-2025-2187

Published: 2025

Journal Articles

MGUS like phenotype in patients with AL amyloidosis: Impact on clinical outcomes for patients treated with bortezomib-containing regimens (BCR).

Victor Jimenez-Zepeda, Etienne Mahe, Sylvia McCulloch, Jason Tay, Peter Duggan

Blood (2025) 146 (Supplement 1): 3963.

https://doi.org/10.1182/blood-2025-3963

Published: 2025

Journal Articles

Outcomes of autologous stem cell transplantation using busulfan-melphalan conditioning with pharmacokinetic monitoring for relapsed diffuse large B-cell lymphoma

Colin Stewart, Kevin Hay, Peter Duggan, Jan Storek, Mona Shafey, Irwindeep Sandhu, Michelle Dowhan, Robert Puckrin

Blood (2025) 146 (Supplement 1): 2761.

https://doi.org/10.1182/blood-2025-2761

Published: 2025

Journal Articles

Improving the Utilization and Tolerability of Thiotepa-Based Autologous Stem Cell Transplantation in Primary CNS Lymphoma

Robert Puckrin, Colin Stewart, Carolyn Owen, Lesley E. Street, Sarah Perry, Peter Duggan, Mona Shafey, Neil Chua, Douglas A. Stewart

Blood (2023) 142 (Supplement 1): 3595.

https://doi.org/10.1182/blood-2023-178085

Published: 2023

Journal Articles

Real-World Outcomes of Consolidative Autotransplant for High-Risk Large B-Cell Lymphoma

Robert Puckrin, Russell Sterrett, Neil Chua, Carolyn Owen, Peter Duggan, Mona Shafey, Douglas A. Stewart

Blood (2022) 140 (Supplement 1): 10581–10582.

https://doi.org/10.1182/blood-2022-162850

Published: 2022

Journal Articles

Alberta Cellular and Immunotherapy (ACIT) 001, Results of Decentralized Production of Second Generation, Anti-CD19/41BB/CD3z Chimeric Antigen Receptor (CAR) T-Cells in Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) and Aggressive Non-Hodgkin Lymphoma (NHL)

Michael P. Chu, Zack M. Breckenridge, Andrew Daly, Mona Shafey, Victor A. Lewis, Sunil J. Desai, Peng Wang, Joseph Brandwein, Peter Duggan, Beverly Wilson, Bindu Thapa, Carina Debes-Marun, Irwindeep Sandhu

Blood (2022) 140 (Supplement 1): 7466–7467.

https://doi.org/10.1182/blood-2022-165887

Published: 2022

Journal Articles

Is Tandem ASCT Needed in MM Patients with High Risk Cytogenetics in the Era of Maintenance Therapy? Results from the Canadian Myeloma Research Group (CMRG) Database

Peter Duggan, MD FRCPC, Donna E. Reece, MD, Kevin Song, MD, Victor Jimenez-Zepeda, MD, Arleigh McCurdy, MD BSc, Martha L Louzada, MDMSc, Hira S Mian, MD, Michael Sebag, MD PhD FRCPC, Darrell J White, MD, Julie Stakiw, MD, Richard Leblanc, MD FRCPC, Esther Masih-Khan, Eshetu G Atenafu, M.Sc., P.Stat, Rami Kotb, MD, Muhammad Aslam, MD, Anthony Reiman, MD, Engin Gul, BS, MBA, Christopher P. Venner, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-139689

Published: 2020

Journal Articles

Cite-Seq Profiling of T Cells in Multiple Myeloma Patients Undergoing BCMA Targeting CAR-T or Bites Immunotherapy

Noemie Leblay, PhD, Ranjan Maity, PhD, Elie Barakat, Sylvia McCulloch, MD MSc, Peter Duggan, MD FRCPC, Victor Jimenez-Zepeda, MD, Nizar J. Bahlis, MD, Paola Neri, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-137650

Published: 2020

Journal Articles

Monoclonal Gammopathy of Clinical Significance - a Single Center Experience

Holly Lee, MD, Lesley Street, MD, Jason Tay, MD, Jennifer Grossman, MD, John F Thaell, MD, Dawn Goodyear, MD, Sylvia McCulloch, MD, Peter Duggan, MD, Paola Neri, MD, Victor Jimenez-Zepeda, MD

Blood (2018) 132 (Supplement 1): 4495.

https://doi.org/10.1182/blood-2018-99-117819

Published: 2018

Journal Articles

Monoclonal Gammopathy of Undetermined Significance - Patient Characteristics and Referral Patterns

Holly Lee, MD, Lesley Street, MD, Jason Tay, MD, Jennifer Grossman, MD, John F Thaell, MD, Dawn Goodyear, MD, Sylvia McCulloch, MD, Peter Duggan, MD, Paola Neri, MD, Victor Jimenez-Zepeda, MD

Blood (2018) 132 (Supplement 1): 4496.

https://doi.org/10.1182/blood-2018-99-117930

Published: 2018

Journal Articles

Identification of Specificity Groups in Myeloma Patients T Cell Receptor (TCR) Repertoire through Single Cell TCR Sequencing

Paola Neri, MD, Ranjan Maity, PhD, Sylvia McCulloch, MD, Peter Duggan, MD, Victor Jimenez-Zepeda, MD, Jason Tay, MD, Nizar Bahlis, MD

Blood (2018) 132 (Supplement 1): 4459.

https://doi.org/10.1182/blood-2018-99-117482

Published: 2018

Journal Articles

Immunome Single Cell Profiling Reveals T Cell Exhaustion with Upregulation of Checkpoint Inhibitors LAG3 and Tigit on Marrow Infiltrating T Lymphocytes in Daratumumab and IMiDs Resistant Patients

Paola Neri, MD, Ranjan Maity, PhD, Ines Tagoug, PhD, Sylvia McCulloch, MD, Peter Duggan, MD, Victor Jimenez-Zepeda, MD, Jason Tay, MD, Anjan Thakurta, PhD, Nizar Bahlis, MD

Blood (2018) 132 (Supplement 1): 242.

https://doi.org/10.1182/blood-2018-99-117531

Published: 2018

Journal Articles

Minimal Residual Disease (MRD) Assessed By Flow Cytometry in Patients with AL Amyloidosis Treated with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD)

Victor Jimenez-Zepeda, MD, Peter Duggan, MD FRCPC, Paola Neri, MD, Jason Tay, MD FRCPC, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 1836.

https://doi.org/10.1182/blood.V130.Suppl_1.1836.1836

Published: 2017

Journal Articles

The Evolving Impact on Survival Outcomes in Multiple Myeloma with Greater Access to Novel Treatment Regimens: Experience in a Real-World Cohort

Zack M. Breckenridge, BSc, Victor Jimenez-Zepeda, MD, Nizar J. Bahlis, MD, Paola Neri, MD, Irwindeep Sandhu, MDFRCPC, Michael P. Chu, MD, Ismail Ismail, Jason Tay, MD FRCPC, Peter Duggan, MD FRCPC, Andrew Belch, Joanne D. Hewitt, NP, PhD, Linda M. Pilarski, PhD, Tatiana Nikitina, Christopher P. Venner

Blood (2017) 130 (Supplement 1): 1859.

https://doi.org/10.1182/blood.V130.Suppl_1.1859.1859

Published: 2017

Journal Articles

Phase I/II Study of Infusional Gemcitabine and High-Dose Melphalan Conditioning Prior to Autologous Stem Cell Transplantation for Patients with Relapsed/Refractory Lymphoma: Interim Safety Analysis

Marta Davidson, MDPhD, Douglas A. Stewart, Peter Duggan, MD FRCPC, Andrew Daly, MD, Mona Shafey, MD

Blood (2017) 130 (Supplement 1): 4534.

https://doi.org/10.1182/blood.V130.Suppl_1.4534.4534

Published: 2017

Journal Articles

Single Cell Resolution Profiling Defines the Innate and Adaptive Immune Repertoires Modulated By Daratumumab and IMiDs Treatment in Multiple Myeloma (MM)

Paola Neri, MD, Ranjan Maity, PhD, Ines Tagoug, PhD, Peter Duggan, MD FRCPC, Sylvia McCulloch, MD, Victor Jimenez-Zepeda, MD, Jason Tay, MD FRCPC, Lawrence H. Boise, PhD, Anjan Thakurta, PhD, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 123.

https://doi.org/10.1182/blood.V130.Suppl_1.123.123

Published: 2017

Journal Articles

Early Relapse in Transplant-Eligible MM Patients Undergoing Auto-SCT Followed By Maintenance Therapy

Victor Jimenez-Zepeda, MD, Peter Duggan, MD FRCPC, Paola Neri, MD, Jason Tay, MD FRCPC, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 5523.

https://doi.org/10.1182/blood.V130.Suppl_1.5523.5523

Published: 2017

Journal Articles

Post-Autologous Stem Cell Transplantation Therapy for Multiple Myeloma Patients: Impact on Clinical Outcomes

Victor Jimenez-Zepeda, MD, Peter Duggan, MD FRCPC, Paola Neri, MD, Jason Tay, MD FRCPC, Sylvia McCulloch, MD, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 5524.

https://doi.org/10.1182/blood.V130.Suppl_1.5524.5524

Published: 2017

Journal Articles

Bortezomib-Maintenance for Patients with AL Amyloidosis: A Single Center Experience

Victor Jimenez-Zepeda, MD, Peter Duggan, MD FRCPC, Paola Neri, MD, Jason Tay, MD FRCPC, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 3151.

https://doi.org/10.1182/blood.V130.Suppl_1.3151.3151

Published: 2017

Journal Articles

Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to Bortezomib, Thalidomide and Dexamethasone (VTD) As Induction Therapy for the Treatment of Transplant Eligible Multiple Myeloma

Victor Jimenez-Zepeda, MD, Nizar J. Bahlis, MD, Peter Duggan, MD, Rafael Alonso, MD, Juan José Lahuerta, MD PhD, Antonio Valeri, Paola Neri, MD PhD, Jason Tay, MD FRCPC MSc, Joaquin Martinez-Lopez

Blood (2016) 128 (22): 4505.

https://doi.org/10.1182/blood.V128.22.4505.4505

Published: 2016

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Light-chain MGUS defined as per the revised definition of the istopmm study: Experience from the university of calgary MGUS clinic

MGUS like phenotype in patients with AL amyloidosis: Impact on clinical outcomes for patients treated with bortezomib-containing regimens (BCR).

Outcomes of autologous stem cell transplantation using busulfan-melphalan conditioning with pharmacokinetic monitoring for relapsed diffuse large B-cell lymphoma

Improving the Utilization and Tolerability of Thiotepa-Based Autologous Stem Cell Transplantation in Primary CNS Lymphoma

Real-World Outcomes of Consolidative Autotransplant for High-Risk Large B-Cell Lymphoma

Alberta Cellular and Immunotherapy (ACIT) 001, Results of Decentralized Production of Second Generation, Anti-CD19/41BB/CD3z Chimeric Antigen Receptor (CAR) T-Cells in Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) and Aggressive Non-Hodgkin Lymphoma (NHL)

Is Tandem ASCT Needed in MM Patients with High Risk Cytogenetics in the Era of Maintenance Therapy? Results from the Canadian Myeloma Research Group (CMRG) Database

Cite-Seq Profiling of T Cells in Multiple Myeloma Patients Undergoing BCMA Targeting CAR-T or Bites Immunotherapy

Monoclonal Gammopathy of Clinical Significance - a Single Center Experience

Monoclonal Gammopathy of Undetermined Significance - Patient Characteristics and Referral Patterns

Identification of Specificity Groups in Myeloma Patients T Cell Receptor (TCR) Repertoire through Single Cell TCR Sequencing

Immunome Single Cell Profiling Reveals T Cell Exhaustion with Upregulation of Checkpoint Inhibitors LAG3 and Tigit on Marrow Infiltrating T Lymphocytes in Daratumumab and IMiDs Resistant Patients

Minimal Residual Disease (MRD) Assessed By Flow Cytometry in Patients with AL Amyloidosis Treated with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD)

The Evolving Impact on Survival Outcomes in Multiple Myeloma with Greater Access to Novel Treatment Regimens: Experience in a Real-World Cohort

Phase I/II Study of Infusional Gemcitabine and High-Dose Melphalan Conditioning Prior to Autologous Stem Cell Transplantation for Patients with Relapsed/Refractory Lymphoma: Interim Safety Analysis

Single Cell Resolution Profiling Defines the Innate and Adaptive Immune Repertoires Modulated By Daratumumab and IMiDs Treatment in Multiple Myeloma (MM)

Early Relapse in Transplant-Eligible MM Patients Undergoing Auto-SCT Followed By Maintenance Therapy

Post-Autologous Stem Cell Transplantation Therapy for Multiple Myeloma Patients: Impact on Clinical Outcomes

Bortezomib-Maintenance for Patients with AL Amyloidosis: A Single Center Experience

Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to Bortezomib, Thalidomide and Dexamethasone (VTD) As Induction Therapy for the Treatment of Transplant Eligible Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only